Login to Your Account



Phase III Clinical Trials Update: October 2011


Monday, November 14, 2011

Company (Location)

Product

Description

Indication

Status (Date)#


AUTOIMMUNE

AB Science SA (Paris)

Masitinib

Orally administered tyrosine kinase inhibitor

Multiple myeloma

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription